Refine
Has Fulltext
- yes (13)
Is part of the Bibliography
- yes (13) (remove)
Document Type
- Journal article (13)
Language
- English (13)
Keywords
- cancer (2)
- gastric cancer (2)
- gemcitabine (2)
- survival (2)
- 5-Fluorouracil (1)
- BCOR (1)
- BCORL1 (1)
- CA19-9 (1)
- CD4(+) (1)
- FOLFIRI (1)
- FOLFOX (1)
- Improved survival (1)
- Interleukin-2 (1)
- MTB (1)
- NGS (1)
- NK cells (1)
- POU6F2-AS2 (1)
- Rectal cancer (1)
- TME (1)
- acute myeloid leukemia (1)
- acute myeloid-leukemia (1)
- adenocarcinoma of the ampulla of Vater (1)
- adjuvant (1)
- adoptive transfer (1)
- biophosphonate (1)
- cancer care (1)
- cancer immunotherapy (1)
- cfRNA (1)
- chemotherapy (1)
- cholestasis (1)
- colorectal cancer (1)
- complication (1)
- comprehensive management (1)
- ddPCR (1)
- early detection (1)
- fear of progression (1)
- folinic acid (1)
- gammadelta T cells (1)
- haploidentical γδ T lymphocytes (1)
- immunosurveillance (1)
- immunotherapy (1)
- in vivo cell expansion (1)
- infusion (1)
- innate immunity (1)
- intestinal-type adenocarcinoma (1)
- irinotecan (1)
- liquid biopsy (1)
- locally advanced disease (1)
- loss-of-function (1)
- multimodal (1)
- nab-paclitaxel (1)
- nanoparticle albumin-bound paclitaxel (1)
- neoadjuvant (1)
- neoadjuvant chemotherapy (1)
- oral anticancer drugs (1)
- outcomes research (1)
- outreach (1)
- oxaliplatin (1)
- pancreatic adenocarcinoma (PDAC) (1)
- pancreatic cancer (1)
- pancreatic head cancer (1)
- pancreatobiliary type (1)
- patient access (1)
- precision oncology (1)
- real world data (1)
- risk factor (1)
- risk stratification (1)
- screening for distress (1)
- stimulation (1)
Institute
- Medizinische Klinik und Poliklinik II (13) (remove)
EU-Project number / Contract (GA) number
- 641458 (1)
Background
International consensus criteria (ICC) have redefined borderline resectability for pancreatic ductal adenocarcinoma (PDAC) according to three dimensions: anatomical (BR-A), biological (BR-B), and conditional (BR-C). The present definition acknowledges that resectability is not just about the anatomic relationship between the tumour and vessels but that biological and conditional dimensions also are important.
Methods
Patients’ tumours were retrospectively defined borderline resectable according to ICC. The study cohort was grouped into either BR-A or BR-B and compared with patients considered primarily resectable (R). Differences in postoperative complications, pathological reports, overall (OS), and disease-free survival were assessed.
Results
A total of 345 patients underwent resection for PDAC. By applying ICC in routine preoperative assessment, 30 patients were classified as stage BR-A and 62 patients as stage BR-B. In total, 253 patients were considered R. The cohort did not contain BR-C patients. No differences in postoperative complications were detected. Median OS was significantly shorter in BR-A (15 months) and BR-B (12 months) compared with R (20 months) patients (BR-A vs. R: p = 0.09 and BR-B vs. R: p < 0.001). CA19-9, as the determining factor of BR-B patients, turned out to be an independent prognostic risk factor for OS.
Conclusions
Preoperative staging defining surgical resectability in PDAC according to ICC is crucial for patient survival. Patients with PDAC BR-B should be considered for multimodal neoadjuvant therapy even if considered anatomically resectable.